Related Experiment Video

Updated: Nov 23, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.6K

Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews

Marina T Van Leeuwen1, Steven Luu1, Howard Gurney2

  • 1Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia.

JNCI Cancer Spectrum
|January 4, 2021
PubMed
Abstract

Insights

Targeted cancer therapies can cause cardiovascular toxicity. This review synthesizes evidence on the cardiovascular risks of 18 targeted agents, aiding clinical management.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Targeted cancer therapies are increasingly used.
  • Cardiovascular toxicity is a known concern with these agents.
  • Systematic evidence synthesis and quality assessment are lacking.

Purpose of the Study:

  • To systematically review and synthesize evidence on the cardiovascular toxicity of targeted cancer therapies.
  • To assess the quality of evidence for these associations.

Main Methods:

  • Searched MEDLINE, Embase, and Cochrane Database for systematic reviews with meta-analyses of cardiovascular outcomes.
  • Included reviews published up to May 2020.
  • Classified evidence of toxicity (sufficient, probable, possible, indeterminate) based on statistical significance, study quality, and size.

Main Results:

  • Identified probable evidence of cardiovascular toxicity for 18 targeted agents.
  • Common toxicities include hypertension, arterial and venous thromboembolism, and left ventricular ejection fraction decline.
  • Specific agents like bevacizumab, abiraterone, and trastuzumab showed significant cardiovascular risks.

Conclusions:

  • Provides a synthesized summary of cardiovascular toxicity associated with targeted therapies.
  • Aims to assist clinicians and patients in managing cardiovascular health during treatment.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.1K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.7K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
17.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K